[What is assured in therapy of gastrointestinal diseases with drugs acting on motility?].
Müller-Lissner
S
S
Abteilung für Gastroenterologie, Medizinische und Chirurgische Klinik Innenstadt der Universität München.
Klauser
A
A
D001285:Atropine / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D020117:Cisapride; D004298:Dopamine / Q000627:therapeutic use; D018492:Dopamine Antagonists; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009294:Narcotics / Q000627:therapeutic use; D009566:Nitrates / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D013566:Sympathomimetics / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D018492:Dopamine Antagonists; D009292:Narcotic Antagonists; D009294:Narcotics; D009566:Nitrates; D010277:Parasympathomimetics; D010880:Piperidines; D013566:Sympathomimetics; D001285:Atropine; D020117:Cisapride; D004298:Dopamine
Was ist gesichert in der Therapie gastrointestinaler Erkrankungen mit motilitätswirksamen Pharmaka?